8-K: NEXGEL Reports Record Third Quarter Revenue, Driven by Branded Consumer Products and Contract Manufacturing

NEXGEL announced record third-quarter revenue of $2.94 million, a 141% increase year-over-year and 104% sequentially, driven by growth in branded consumer products and contract manufacturing.

Summary

• NEXGEL reported a record third-quarter revenue of $2.94 million, marking a 141% increase compared to the same quarter last year and a 104% increase compared to the previous quarter.
• The company's revenue growth was fueled by a 99% sequential increase in branded consumer products and a 103% sequential increase in contract manufacturing.
• Gross profit margin for the quarter was 43.6%, a significant improvement from 28.2% in Q3 2023 and 28.5% in Q2 2024.
• The net loss for the quarter was $754,000, compared to a net loss of $552,000 in Q3 2023 and $979,000 in Q2 2024.
• Adjusted EBITDA loss was $347,000, an improvement from $464,000 in Q3 2023 and $788,000 in Q2 2024.
• As of September 30, 2024, the company had a cash balance of $1.10 million.
• Subsequent to the end of the quarter, NEXGEL closed a registered direct offering for gross proceeds of $2 million.

Sentiment

Score: 8

Explanation: The document shows strong positive trends in revenue growth and gross profit margin, with a clear path towards profitability. The successful capital raise further strengthens the company's position. However, the net loss and increased expenses temper the overall sentiment slightly.

Positives

• The company experienced substantial revenue growth, with a 141% year-over-year increase and a 104% sequential increase.
• Gross profit margins significantly improved to 43.6%, indicating better profitability.
• Adjusted EBITDA loss decreased, showing progress towards profitability.
• The company successfully raised $2 million through a registered direct offering to support growth.
• Both branded consumer products and contract manufacturing saw significant sequential growth of approximately 100%.

Negatives

• The company reported a net loss of $754,000 for the quarter, although this was an improvement from the previous quarter.
• Selling, general, and administrative expenses increased by $1.12 million, or approximately 118%, primarily due to increased advertising, marketing, and Amazon fees.
• The company's cash balance was $1.1 million as of September 30, 2024, which may be considered low for a growing company.

Risks

• The company is still operating at a loss, with a net loss of $754,000 for the quarter.
• Increased selling, general, and administrative expenses could impact profitability if not managed effectively.
• The company's cash balance of $1.1 million may not be sufficient to support future growth without additional funding.
• The company's future performance is subject to risks and uncertainties, as outlined in their annual report on Form 10-K.

Future Outlook

The company expects year-over-year and sequential revenue growth to continue in the fourth quarter and anticipates that the quarterly Non-GAAP EBITDA loss will narrow further. The company also expects the first orders of SilverSeal to Cintas to occur in the fourth quarter.

Management Comments

• Adam Levy, NEXGEL's Chief Executive Officer, stated that the third quarter was another record quarter across all key financial measures.
• He noted that significant growth was driven by approximately 100% sequential growth in both branded consumer products and contract manufacturing.
• He also mentioned that the company strengthened its balance sheet with the closing of $2 million in gross proceeds from a registered direct offering.

Industry Context

NEXGEL operates in the healthcare and consumer products industry, focusing on hydrogel technology. The company's growth in both branded consumer products and contract manufacturing suggests a strong market demand for its offerings. The increase in revenue and gross profit margin indicates a positive trend in the company's performance within its sector.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 141% year-over-year revenue growth and the improvement in gross profit margin to 43.6% are strong indicators of performance compared to industry averages.
• Companies like 3M and Johnson & Johnson, which also operate in the healthcare and consumer product space, typically have more established revenue streams and higher profit margins, but NEXGEL's growth rate suggests it is rapidly gaining market share.
• The company's focus on high-water-content hydrogels is a niche market, and its performance should be compared to other companies specializing in similar technologies, although specific comparables are not mentioned in the document.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved gross profit margin positively.
• Employees may benefit from the company's growth and potential future profitability.
• Customers will have access to the company's products, which are experiencing high demand.
• Suppliers may see increased orders due to the company's growth.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company expects continued revenue growth in the fourth quarter.
• The company anticipates further narrowing of the quarterly Non-GAAP EBITDA loss.
• The first orders of SilverSeal to Cintas are expected to occur in the fourth quarter.

Key Dates

Keywords

NEXGEL, hydrogel, revenue, gross profit, EBITDA, consumer products, contract manufacturing, financial results, registered direct offering